Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Julphar
UBS
Teva
Healthtrust
Accenture
Fish and Richardson
Express Scripts
McKinsey

Generated: July 20, 2018

DrugPatentWatch Database Preview

IVERMECTIN - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for ivermectin and what is the scope of ivermectin freedom to operate?

Ivermectin
is the generic ingredient in four branded drugs marketed by Galderma Labs Lp, Arbor Pharms Llc, Edenbridge Pharms, and Merck Sharp Dohme, and is included in four NDAs. There are fifteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ivermectin has eighty-four patent family members in twenty-eight countries.

There are five drug master file entries for ivermectin. Eight suppliers are listed for this compound.
Pharmacology for IVERMECTIN
Medical Subject Heading (MeSH) Categories for IVERMECTIN
Synonyms for IVERMECTIN
(1'R,2R,4'S,10'E,14'E,16'E,21'R)-6-(butan-2-yl)-21',24'-dihydroxy-12'-{[(2R,4S,6S)-5-{[(2S,4S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxa
(2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-Butan-2-Yl]-20,20b-Dihydroxy-5',6,8,19-Tetramethyl-17-Oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-Tetradecahydro-2h,7h-Spiro[11,15-Methanofuro[4,3,2-Pq][2,
(2R,5'S,6'R)-dihydroxy-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyl-tetrahydropyran-2-yl]oxy-4-methoxy-6-methyl-tetrahydropyran-2-yl]oxy-5'-tetramethyl-6'-[(1S)-1-methylpropyl]spiro[[?]-2,2'-tetrahydropyran]on
(Unlabeled)Ivermectin-d2
116522-39-5
123022-60-6
139645-33-3
22,23-Dihydro C-076B1
22,23-Dihydro-5-O-demethylavermectin A1a
22,23-Dihydroavermectin B(1)a
22,23-Dihydroavermectin B1|||Heartgard 30|||Ivomec|||Ivosint|||Mectizan|||Stromectol|||Uvemec|||Vermic|||Zimecterin
22,23-Dihydroavermectin B1a
288I867
5-O-demethyl-22,23-dihydroavermectin A1a
70161-11-4
70288-86-7
71827-03-7
73910-57-3
91Y2202OUW
AB00513813
AB00513813_04
AB00513813-02
AB00513813-03
AB01563172_01
AC1MJ4GR
AC1N7O27
AKOS015969666
AKOS027470116
AS-14167
Avermectin A1a, 22,23-dihydro-5-O-demethyl-
Avermectin A1a, 5-O-demethyl-22,23-dihydro-
avermectin H2B1a
AZSNMRSAGSSBNP-XPNPUAGNSA-N
BDBM50409816
Bio-0055
BPBio1_000322
BRD-A48570745-001-01-1
BRD-K24652731-001-02-7
BRN 4643153
BSPBio_000292
C48H74O14 (B1a form)
CA011349
CAS-71827-03-7
CCG-204778
CCG-213693
CCG-220156
CHEBI:63941
CHEBI:91732
CHEBI:94551
CHEMBL1699565
CHEMBL1876587
CHEMBL263291
D09YHJ
dihydro avermectin Bla
Dihydroavermectin B1a
DSSTox_CID_3181
DSSTox_GSID_23181
DSSTox_RID_76909
DTXSID8023181
EINECS 276-046-2
EU-0100693
FT-0082656
GTPL2373
H2B1a
Heartgard 30
HMS1568O14
HMS2089M09
HMS2091E11
HMS2095O14
HMS2233J07
HMS3262K07
I 8898
I1850
Ivermectin (MK-0933)
Ivermectin B1a
Ivermectin-d2
Ivermectin, Antibiotic for Culture Media Use Only
Ivermectin, European Pharmacopoeia (EP) Reference Standard
Ivermectin, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Ivermectin, United States Pharmacopeia (USP) Reference Standard
IvermectinB1a
Ivexterm (TN)
IVM
Ivosint
J10179
Lopac0_000693
LP00693
Mectizan (TN)
MK-933
MLS001333247
MLS001333248
MLS002153248
MolPort-006-394-715
MolPort-020-015-936
MolPort-044-878-307
NCGC00094047-01
NCGC00094047-02
NCGC00163233-01
NCGC00186639-01
NCGC00261378-01
NSC-755843
NSC755843
Pharmakon1600-01300027
Prestwick_516
Prestwick2_000156
Prestwick3_000156
Q-201262
RL04692
s1351
SCHEMBL13259385
SCHEMBL17212450
SCHEMBL312795
Sklice
SMR000857211
Soolantra
SR-01000075941
SR-01000075941-1
Stromectol (TN)
Tox21_112034
Tox21_500693
UNII-8883YP2R6D component AZSNMRSAGSSBNP-XPNPUAGNSA-N
UNII-91Y2202OUW
VA11120
ZINC238808778
ZINC252286706
ZINC253630390
ZINC301054281

US Patents and Regulatory Information for IVERMECTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Arbor Pharms Llc SKLICE ivermectin LOTION;TOPICAL 202736-001 Feb 7, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for IVERMECTIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,598,129 Topical application of ivermectin for the treatment of dermatological conditions/afflictions ➤ Try a Free Trial
8,624,678 Output stage of a power amplifier having a switched-bulk biasing and adaptive biasing ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for IVERMECTIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000079 Germany ➤ Try a Free Trial PRODUCT NAME: IVERMECTIN ZU SEINER VERWENDUNG FUER DIE BEHANDLUNG VON ROSAZEA; NAT. REGISTRATION NO/DATE: 92429.00.00 20150429; FIRST REGISTRATION: MALTA MA 117/01101 20150402
/2015 Austria ➤ Try a Free Trial PRODUCT NAME: IVERMECTIN; NAT. REGISTRATION NO/DATE: 136170 20150602; FIRST REGISTRATION: MT MA 117/01101 20150402
C0069 France ➤ Try a Free Trial PRODUCT NAME: IVERMECTINE; NAT. REGISTRATION NO/DATE: NL 44511 20150721; FIRST REGISTRATION: MT - MA 117/01101 20150402
00756 Netherlands ➤ Try a Free Trial PRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN; NAT. REGISTRATION NO/DATE: RVG 115310 20150504; FIRST REGISTRATION: MA117/01101 20150402
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Dow
Fuji
Farmers Insurance
US Army
Queensland Health
Harvard Business School
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.